Abstract
A 69-year-old man with recurrent postoperative lung adenocarcinoma (negative for EGFR mutation and ALK rearrangement) was administered a combination therapy of pembrolizumab, carboplatin, and pemetrexed every 3 weeks. He received four cycles of induction treatment and one cycle of maintenance treatment with pembrolizumab and pemetrexed. Dexamethasone (9.9 mg for induction treatment and 6.6 mg for maintenance treatment) was used only on day 1 of each cycle because he had poorly controlled diabetes mellitus.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.